Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Targeted Delivery of Anti-Inflammatory Agents to Tumors

Author(s): Maria Coimbra, Sylvia A. Kuijpers, Sebastiaan P. van Seters, Gert Storm and Raymond M. Schiffelers

Volume 15, Issue 16, 2009

Page: [1825 - 1843] Pages: 19

DOI: 10.2174/138161209788453220

Price: $65

Abstract

Inflammation is considered a hallmark of cancer. The chronic inflammatory process is driven by the interaction of cells, proteins, cytokines, transcription factors, and lipid mediators within the tumor microenvironment giving rise to complex pro-inflammatory cascades. These can be inhibited by a variety of different anti-inflammatory compounds, like non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory biologicals, phytotherapeutics (mainly polyphenols), and drugs with pleiotropic anti-inflammatory effects. In general, it appears that the anti-tumor activity of these compounds occurs at higher doses than the doses used in conventional anti-inflammatory therapy. To optimally take advantage of the anti-tumor activity and at the same time limit side effects, targeted delivery of anti-inflammatory drugs appears an attractive approach.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy